Breaking AI & Tech News Analyzed

Trump Media and Technology Group (TMTG), the parent company of the Truth Social platform, has formally withdrawn its defamation claim against The Guardian and two additional defendants. The suit had challenged a March 2023 Guardian report alleging that federal prosecutors were investigating $8 million in payments received by TMTG from entities with connections to Russian President Vladimir Putin. The dismissal was filed in the 12th Judicial Circuit Court in Sarasota County, Florida, on Friday. By withdrawing without prejudice, TMTG retains the option to re‑file the case at a future date. The Guardian’s original article said New York prosecutors opened a criminal inquiry into money wired to TMTG via the Caribbean by two parties that appeared to be partially controlled by an associate of a Putin ally. At the time, TMTG was preparing for a merger with Digital World Acquisition Corp (DWAC) that would have created a company valued at roughly $1.3 billion. Feeling vulnerable to accusations of receiving funds from a potentially hostile source, TMTG sued for libel, asserting that the Guardian’s statements were false and defamatory. In November, Judge Hunter W. Carroll dismissed the case against Guardian News and Media Ltd., Penske Media Corporation (owner of Variety), and former TMTG founder‑turned‑whistleblower Will Wilkerson, citing a failure to prove actual malice. Carroll, appointed by former Florida Governor Rick Scott, allowed TMTG to file an amended complaint, which the company did in January. A hearing was scheduled for the following Tuesday, but TMTG’s sudden withdrawal halted the proceedings. No reason was provided for the abrupt change. The Guardian has been contacted for comment. In April 2024, a lawyer for Trump sent The Guardian a letter calling its reporting “false” and a “hoax,” insisting that litigation would continue until the outlet retracted the story. Despite the legal tussle, there is no evidence that TMTG or its executives knowingly concealed the origin of the loans. No criminal charges have been brought against the company. Guardian News and Media responded, welcoming the voluntary dismissal and emphasizing that its reporting was based on meticulous fact‑checking, credible sources, and thorough documentation, while characterizing TMTG’s claims as meritless. The dismissal marks a rare retreat for Trump’s legal team, which has pursued an increasingly aggressive strategy against media outlets during his second presidential term, securing several high‑profile settlements with broadcasters such as ABC and CBS. Trump is currently pursuing a $15 billion defamation suit against The New York Times and a $10 billion claim against the BBC, alleging editorial manipulation of his speeches. Both cases have been described by the defendants as groundless and potentially chilling to press freedom. The Guardian’s investigation focused on two emergency loans TMTG received in December 2021 and February 2022, when the company faced a financial crisis after its merger with DWAC was delayed by SEC and FINRA investigations. Wire‑transfer records traced a $2 million payment through Paxum Bank, a Dominica‑registered institution, and a subsequent $6 million payment involving the ES Family Trust, whose trustee also served as a Paxum director. Federal prosecutors in the Southern District of New York examined Paxum Bank’s ownership, identifying a link to Anton Postolnikov, a relative of Aleksandr Smirnov, an associate of Putin.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

A comprehensive study from Denmark has concluded that taking acetaminophen, commonly known as Tylenol, during pregnancy has no effect on later autism diagnoses in children. The research, which utilized Denmark's robust national healthcare system to track more than 1.5 million children born between 1997 and 2022, including 31,098 children who were exposed to Tylenol in utero, found no significant link between Tylenol use and autism. The study's findings contradict claims made by the Trump administration, which had suggested that Tylenol use during pregnancy was a major cause of autism in children. This led to a notable 16% drop in Tylenol orders for pregnant women in emergency rooms following the announcement. However, the new study provides reassurance that Tylenol is safe to use during pregnancy for pain relief and fever reduction. According to the study, autism was diagnosed in 1.8% of children who were exposed to Tylenol and 3% of those who weren’t. A similar 2024 study in Sweden found a marginal link that disappeared after considering siblings, suggesting that autism is strongly genetic. Health officials had previously announced a label change for acetaminophen, warning of a potential link to autism, which has now been called into question. Experts, such as Jeremy Faust, an emergency physician at Mass General Brigham and a health services researcher at Harvard Medical School, have noted that the words of health officials can significantly affect behavior, as evidenced by the drop in Tylenol orders. However, Faust also emphasized that Tylenol remains one of the safest options for pain control and fever reduction during pregnancy.

The 2018 World Cup in Russia served as a high‑profile platform for Vladimir Putin, showcasing his nation and bolstering his personal legitimacy. The tournament was effectively a diplomatic bow to the Kremlin’s ambitions.Fast‑forward to the summer of 2026, and the buildup to the event has taken on a distinctly American flavour, with the competition becoming a backdrop for Donald Trump’s political narrative.The next edition, slated for 2034 in Saudi Arabia, presents a fresh set of challenges. Despite the kingdom’s controversial human‑rights record, the event offers Crown Prince Mohammed bin Salman an opportunity to polish his and the nation’s image. FIFA’s current reluctance to enforce independent oversight of migrant‑worker conditions raises fears that construction could be as deadly as the 2022 Qatar experience.These developments underscore a pressing need to insulate the World Cup from the whims of powerful leaders. One proposed solution is to fragment the tournament—treating it like a monopoly that has become too dominant.Evidence that this approach is feasible already exists: the 2026 World Cup will be co‑hosted by three nations, and the 2030 edition is set to span six countries across three continents (Spain, Portugal, Morocco, Argentina, Paraguay, Uruguay).Building on that, the author suggests a radical redesign: allocate each group stage to a different global city—Paris, Rio de Janeiro, Tokyo, Sydney, Johannesburg, London, the Basque Country, and so on. Knock‑out rounds could be broken into three‑match clusters and scattered worldwide, with the semi‑finals, final, and third‑place match awarded to the highest‑bidding venue.Carbon‑footprint concerns are addressed by noting that teams already travel long distances to a single host nation; distributing groups based on the median distance to participating teams would not significantly increase emissions.Financially, the cost of staging a traditional, single‑host World Cup has ballooned, limiting the pool of viable bidders to those seeking political or economic leverage. A decentralized format would dilute any single leader’s ability—whether Trump, Putin, or the Saudi crown prince—to manipulate the event for personal gain.Decentralisation would still align with FIFA’s stated objectives: expanding the sport’s reach, creating a truly global spectacle, and bringing football closer to fans worldwide.While FIFA claims a fiduciary duty to maximise revenue for its 211 member associations—justifying steep ticket prices and controversial sponsorships—the proposed model could actually enhance revenue by turning each small cluster of matches into premium, high‑value events.Precedent exists in the form of Euro 2020, which, despite being postponed by the pandemic, successfully unfolded across 11 European cities, delivering record‑breaking goal tallies and strong attendance figures.In sum, the most effective way to protect the World Cup’s cultural significance and prevent its exploitation by authoritarian figures may be to deconstruct and disperse it globally, turning a single‑host behemoth into a series of interconnected, locally hosted celebrations of the sport.

A federal judge in Miami has dismissed former President Donald Trump’s defamation lawsuit against the Wall Street Journal and News Corp, granting the former president a two‑week deadline to refile the case. Trump’s suit, filed last summer, alleged that a lewd drawing featured in a July 2025 article—purportedly a “bawdy” birthday letter to the late financier Jeffrey Epstein—was fabricated, and that the newspaper published it with actual malice. The complaint also named media mogul Rupert Murdoch, whose News Corp owns the Journal, as a defendant. Judge Darrin P. Gayles ruled that the complaint “fails to adequately allege actual malice,” the legal standard required for defamation actions by public figures. He noted that the Journal had conducted a “significant” inquiry into the authenticity of the drawing and that Trump’s assertion of falsity alone does not prove the newspaper acted with “serious doubts” about the story’s truth. In his opinion, the judge wrote: “Because President Trump has not plausibly alleged that defendants published the article with actual malice, both counts must be dismissed.” He also observed that Trump’s team had not presented evidence of special damages. Under the order, Trump may refile the lawsuit by April 27 with additional proof that the Journal knowingly published false material. A spokesperson for Trump’s legal team confirmed they will pursue a revised filing, emphasizing the administration’s intent to “hold accountable those who traffic in fake news.” The Wall Street Journal and its parent company, Dow Jones, welcomed the decision. A Dow Jones representative said, “We stand behind the reliability, rigor and accuracy of The Wall Street Journal’s reporting.” The dismissal underscores the stringent “actual malice” requirement for defamation suits involving public officials, a threshold that continues to shape media‑law battles in the United States. It also leaves Trump with ongoing litigation against the BBC and other media outlets over separate First Amendment disputes.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

The ongoing conflict in Iran has created a perilous situation where the threat of nuclear war and climate disruption have converged into a single, catastrophic crisis. This crisis will persist long after the war subsides, emphasizing the need for immediate and decisive action. For over a decade, climate change has been recognized not just as an environmental issue but as a fundamental threat to national and global security. The current situation demands that governments conduct thorough risk assessments and treat climate change with the same urgency as military threats. The war on Iran has several alarming features: Unilateral action: The US and Israel launched a large-scale war against a sovereign nation without consulting major allies, creating a diplomatically isolated conflict with no clear exit strategy. Escalation threats: There are credible threats of escalation from both sides, with Donald Trump issuing ultimatums and Iran threatening to target critical infrastructure. Catastrophic miscalculation: The conditions for miscalculation are ripe, with erratic leadership, intelligence failures, and extreme pressure on decision-makers. The conflict has significant implications: Global energy shock: The closure of the Strait of Hormuz has caused an acute global energy shock, with higher oil prices likely to accelerate inflation and economic instability. Climate impact: The war is consuming military resources and political attention, with no climate dividend, and may pressure countries to extend fossil fuel use. Australia, as a regional power and signatory to the NPT, has responsibilities to the international order. The author, Admiral Chris Barrie, calls on the Australian government to take four key steps: Conduct and release a nuclear escalation risk assessment. Use diplomatic channels to counsel restraint. Refuse any form of complicity in nuclear use. Champion de-escalation at the NPT review conference. Australia can play a crucial role in addressing these threats by acting on evidence, speaking plainly about risks, and leading rather than following events.

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Prince Harry, the youngest son of King Charles III, is facing a defamation lawsuit from Sentebale, the charity he co-founded with Prince Seeiso of Lesotho in honor of Princess Diana. The charity claims that Harry and Mark Dyer, a former trustee, orchestrated a media campaign that caused operational disruption and reputational harm to the organization.The dispute began in 2023 over a new fundraising strategy, leading to Harry and Prince Seeiso stepping down as patrons in March 2025. Sophie Chandauka, the charity's chair, accused Harry of bullying and harassment, but a UK Charity Commission inquiry found no evidence of bullying. The commission did criticize the parties for allowing the internal dispute to become public.Harry's spokesperson has categorically rejected the libel claim, calling it offensive and damaging. The lawsuit, filed in the High Court of England and Wales, seeks the court's intervention, protection, and restitution for the harm caused to Sentebale, its leadership, and strategic partners.